Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Clin Gastroenterol Hepatol. 2023 Oct;21(11):2928-2937.e12. doi: 10.1016/j.cgh.2023.01.033. Epub 2023 Feb 12.
At diagnosis, up to one-third of patients with Crohn's disease (CD) have a complicated phenotype with stricturing (B2) or penetrating (B3) behavior or require early surgery. We evaluated protein biomarkers and antimicrobial antibodies in serum archived years before CD diagnosis to assess whether complicated diagnoses were associated with a specific serological signature.
Prediagnosis serum was obtained from 201 patients with CD and 201 healthy controls. Samples were evaluated with a comprehensive panel of 1129 proteomic markers (SomaLogic) and antimicrobial antibodies. CD diagnosis and complications were defined by the International Classification of Diseases-Ninth Revision and Current Procedural Terminology codes. Cox regression models were utilized to assess the association between markers and the subsequent risk of being diagnosed with complicated CD. In addition, biological pathway and network analyses were performed.
Forty-seven CD subjects (24%) had a B2 (n = 36) or B3 (n = 9) phenotype or CD-related surgery (n = 2) at diagnosis. Subjects presenting with complicated CD at diagnosis had higher levels of antimicrobial antibodies six years before diagnosis as compared with those diagnosed with noncomplicated CD. Twenty-two protein biomarkers (reflecting inflammatory, fibrosis, and tissue protection markers) were found to be associated with complicated CD. Pathway analysis of the altered protein biomarkers identified higher activation of the innate immune system and complement or coagulation cascades up to six years before diagnosis in complicated CD.
Proteins and antimicrobial antibodies associated with dysregulated innate immunity, excessive adaptive response to microbial antigens, and fibrosis precede and predict a complicated phenotype at the time of diagnosis in CD patients.
在诊断时,多达三分之一的克罗恩病(CD)患者具有狭窄(B2)或穿透(B3)行为的复杂表型,或需要早期手术。我们评估了 CD 诊断前数年存档的血清中的蛋白质生物标志物和抗微生物抗体,以评估复杂的诊断是否与特定的血清学特征相关。
从 201 例 CD 患者和 201 例健康对照者中获得预测诊断血清。使用包含 1129 种蛋白质标志物(SomaLogic)和抗微生物抗体的综合检测面板对样本进行评估。CD 诊断和并发症通过国际疾病分类第九版和当前程序术语代码定义。利用 Cox 回归模型评估标志物与随后被诊断为复杂 CD 的风险之间的关联。此外,还进行了生物学途径和网络分析。
47 例 CD 患者(24%)在诊断时具有 B2(n=36)或 B3(n=9)表型或与 CD 相关的手术(n=2)。与被诊断为非复杂 CD 的患者相比,在诊断时表现出复杂 CD 的患者在诊断前六年具有更高水平的抗微生物抗体。22 种蛋白质生物标志物(反映炎症、纤维化和组织保护标志物)与复杂 CD 相关。改变的蛋白质生物标志物的途径分析表明,在复杂 CD 中,固有免疫系统和补体或凝血级联的激活可高达诊断前六年。
与失调的固有免疫、对微生物抗原的过度适应性反应以及纤维化相关的蛋白质和抗微生物抗体在 CD 患者的诊断时就先于并预测出复杂表型。